(VIANEWS) – DANONE (BN.PA), COLAS (RE.PA), SANOFI (SAN.PA) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio at the moment. The payout ratio in itself isn’t a guarantee of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. DANONE (BN.PA)
131.08% Payout Ratio
Danone S.A. operates in the food and beverage industry in Europe, North America, China, North Asia, the Oceania, Latin America, the Asia Pacific, Africa, the Middle East, and the Commonwealth of Independent States. The company operates through three segments: Essential Dairy & Plant-Based, Specialized Nutrition, and Waters. It produces and distributes yogurts; milk products; coffee creamers, beverages, and drinks; plant-based products; and ice creams, frozen desserts, and cheese products under the Actimel, Activia, Alpro, Aptamil, Danette, Danio, Danonino, evian, Nutricia, Nutrilon, Volvic, Danone, Prostokvashino, Light & Free, Oikos, Danissimo, YoPRO, International Delight, SToK, Silk, and So Delicious, as well as under the licensed brand Dunkin' Donuts. The company also provides specialized nutrition products for pregnant and breastfeeding mothers, infants, and young children under the Aptamil, Nutrilon, Gallia, Cow & Gate, Bebelac, Blédina, Olvarit, and Happy Family Organics brands. In addition, it offers tube feeding products under the Nutrison name; oral nutritional supplements under the Fortimel and NutriDrink names; and hypoallergenic products for children with allergies primarily under the Aptamil ProSyneo, Aptamil Pepti Syneo, and Neocate Syneo names. Further, the company provides water with natural fruit extracts, fruit juice, and vitamins under the evian, Volvic, Aqua, Mizone, Bonafont, Salus, Hayat, Sirma, Fontvella, Lanjarón, Zywiec Zdroj, Villavicencio, and Villa del Sur brands. It distributes its products through retail chains and traditional market outlets; convenience stores; hospitals, clinics, and pharmacies; and e-commerce. The company was formerly known as Groupe Danone and changed its name to Danone S.A. in April 2009. Danone S.A. was incorporated in 1899 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, DANONE has a trailing twelve months EPS of €1.48.
PE Ratio
DANONE has a trailing twelve months price to earnings ratio of 36.53. Meaning, the purchaser of the share is investing €36.53 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.78%.
Moving Average
DANONE’s value is under its 50-day moving average of €55.83 and above its 200-day moving average of €53.59.
Yearly Top and Bottom Value
DANONE’s stock is valued at €54.07 at 12:10 EST, way under its 52-week high of €61.88 and way higher than its 52-week low of €46.75.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 9, 2023, the estimated forward annual dividend rate is 2 and the estimated forward annual dividend yield is 3.6%.
Volume
Today’s last reported volume for DANONE is 153889 which is 87.51% below its average volume of 1232720.
More news about DANONE.
2. COLAS (RE.PA)
74.3% Payout Ratio
Colas SA constructs and maintains transport infrastructure worldwide. It operates through three segments: Roads, Construction materials, and Railways. The company constructs and maintains roads and highways; and works on airfield runways and aprons, seaports, industrial sites, logistics and commercial premises, street construction and urban development, reserved-lane public transport, recreational amenities, environmental protection, etc. It also engages in the renovation, demolition, and deconstruction of buildings; and constructs small-scale civil engineering and drainage projects. In addition, the company produces and recycles construction materials, such as aggregates, emulsions and binders, asphalt mixes, ready-mix concrete, and bitumen. Further, it designs and engineers large projects; constructs, renews, and maintains rail networks, such as high-speed and conventional train lines, subways, and tramways; lays and maintains tracks, electrification, signaling/telecommunications, safety systems, ventilation, and fire detection/protection, as well as specific projects comprising bridge cranes, special branch lines, and repair of railway tunnels. Additionally, the company lays and maintains pipes and pipelines for the transport of water and energy, including the construction of turnkey gas compression stations, small-scale civil engineering works, and industrial services. It also engages in the manufacture, installation, and maintenance of road safety and signaling equipment; traffic management activities; and distribution of bitumen. The company was founded in 1929 and is headquartered in Paris, France. Colas SA is a subsidiary of Bouygues SA.
Earnings Per Share
As for profitability, COLAS has a trailing twelve months EPS of €9.34.
PE Ratio
COLAS has a trailing twelve months price to earnings ratio of 12.15. Meaning, the purchaser of the share is investing €12.15 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.72%.
Volume
Today’s last reported volume for COLAS is 285 which is 40.12% below its average volume of 476.
Yearly Top and Bottom Value
COLAS’s stock is valued at €113.50 at 12:10 EST, way under its 52-week high of €127.50 and above its 52-week low of €111.00.
More news about COLAS.
3. SANOFI (SAN.PA)
50.08% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.65.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 14.12. Meaning, the purchaser of the share is investing €14.12 for every euro of annual earnings.
Yearly Top and Bottom Value
SANOFI’s stock is valued at €93.92 at 12:10 EST, way under its 52-week high of €105.18 and way higher than its 52-week low of €76.45.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.1%, now sitting on 46.2B for the twelve trailing months.
More news about SANOFI.
4. REMY COINTREAU (RCO.PA)
32.46% Payout Ratio
Rémy Cointreau SA, together with its subsidiaries, engages in the production, sale, and distribution of liqueurs and spirits. The company operates through Rémy Martin, Liqueurs & Spirits, and Partner Brands segments. It offers liqueurs, brandy, gin, single malt whisky, rum, wine, and champagne primarily under the Cointreau, Metaxa, St-Rémy, Mount Gay, Bruichladdich, Port Charlotte, Octomore, The Botanist, Westland, LOUIS XIII, and Domaine des Hautes Glaces brands. The company operates in Europe, the Middle East, Africa, the Americas, Asia, Australia, and New Zealand. Rémy Cointreau SA was founded in 1724 and is headquartered in Cognac, France.
Earnings Per Share
As for profitability, REMY COINTREAU has a trailing twelve months EPS of €5.7.
PE Ratio
REMY COINTREAU has a trailing twelve months price to earnings ratio of 26.29. Meaning, the purchaser of the share is investing €26.29 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.18%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2.1%, now sitting on 1.55B for the twelve trailing months.
More news about REMY COINTREAU.
